Nyxoah Q2 Revenue Jumps 74 Percent

Nyxoah (NASDAQ:NYXH) reported Q2 2025 earnings, including €1.3 million in revenue (up 73.8% YoY) and a €19.9 million operating loss reflecting significant investment in U.S. commercialization infrastructure. The core development is the FDA Pre-Market Approval for its GENEO system, establishing it as the first and only bilateral hypoglossal nerve stimulation therapy approved in the U.S. for obstructive sleep apnea, directly challenging Inspire Medical. Nyxoah has initiated an immediate U.S. launch with a 50-person commercial team, targeting key implanting accounts, and has already secured early physician training and initial payer approvals, signaling rapid market penetration and setting the stage for future growth, particularly with anticipated label expansion for CCC patients by early 2027.

Analysis

Nyxoah has achieved a pivotal corporate milestone with the U.S. FDA Pre-Market Approval (PMA) for its GENEO system, establishing it as the first and only bilateral hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA) in the market. This approval directly positions the company as a formidable challenger to the incumbent, Inspire Medical. The company's immediate U.S. launch, backed by a 50-person commercial team targeting accounts that constitute 75-80% of market revenue, demonstrates an aggressive market entry strategy. Early execution appears promising, with over 100 physicians already trained and initial payer pre-authorizations secured in the first week. Financially, the 73.8% year-over-year revenue growth to €1.3 million is overshadowed by a €19.9 million operating loss, a figure directly attributable to the upfront investment in U.S. commercial infrastructure. The company's liquidity, consisting of €43 million in cash and access to a €27.5 million debt facility, provides a runway for these initial launch expenses. A key future catalyst is the potential label expansion for complete concentric collapse (CCC) patients, anticipated by early 2027, which would significantly expand the addressable market. However, a notable uncertainty for investors is the absence of explicit 2025 revenue or implant guidance, with major payer coverage decisions not expected until 2026.

Key Decisions for Investors

• Investors should recognize the FDA approval as a significant de-risking event that validates the GENEO system's technology and unlocks the large U.S. market, presenting a potential high-growth opportunity.
• Monitor early commercial traction very closely, specifically initial implant numbers and physician adoption rates in the coming quarters, as the lack of company guidance makes these execution metrics the primary indicators of launch success.
• Evaluate the company's cash burn rate against its €43 million cash position and available debt, as the significant operating loss indicates that the current capital may be consumed rapidly to fund the U.S. launch, potentially necessitating future financing.
• Track the progress of the PMA supplement for CCC patients, as a successful label expansion by the targeted early 2027 timeline would serve as a major long-term growth catalyst and differentiate Nyxoah's offering further.